Anti-cancer Potentiality of Saffron Against Hepatocellular Carcinoma

NCT06464380 · tracked via the Priya Life Science Egypt tracker

Sponsor

Ain Shams University

Phase

Phase 4

Started

2024-10-30

Last updated

2024-09-23

Condition(s) studied

Hepatocellular Carcinoma

Investigational drug(s) / intervention(s)

SaffranalPlacebo

Saffranal: HCC patients will receive 50 mg safranal regimen in dose of once per day for six months.

Placebo: HCC patients will receive Placebo in dose of once per day for six months.

Study summary

Saffron has recently gained considerable interest for its capacity to interfere with cancer at initiation and promotion stages as well as for cancer treatment. Although saffron and its constituents have been shown to have antitumorigenic and proapoptotic activities in different cancer cell lines.

The aim of the current investigation is to identify the anti-cancer potentiality of saffron on hepatocellular carcinoma patients.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Adult male and female patients above 18 years * Patients with end-stage HCC not candidate for curative, loco regional treatment and /or systemic chemotherapy * Patients with available baseline laboratory parameters and contrast- enhancing images after given written consent for research participation. Exclusion Criteria: * Patients who are candidate for curative and/or loco-regional or combination treatment for HCC * Patients with concomitant malignancies other than HCC

Primary outcome measure(s)

overall survival — three months
overall survival in patients presented with end-stage hepatocellular carcinoma.

Trial sites (2)

Facility	City	Region	Status
Amal A. Elkholy	Al ‘Abbāsīyah	Al Abbasiya
Dermatology Clinic of National Hepatology and Tropical Medicine Research Institute	Cairo	Egypt

More Ain Shams University trials in Egypt

Iliopsoas Nerve Block and Femoral Nerve Block in Hip Fracture Surgeries Recruiting

Comparative Study Between Pericapsular Nerve Group Block (PENG) And Pericapsular Nerve Group (PENG) Block Combined With Lateral Femoral Cutaneous Nerve (LFCN) Block for Positioning Analgesia Prior to Spinal Anesthesia in Hip Fracture Patients Recruiting

Neutrophils to Lymphocytes and Platelets Ratio, Procalcitonin, and Total Leucocytic Count as Indicators of Prognostic Outcome in Septic Patients in the Intensive Care Unit. Recruiting

Palmitoylethanolamide in Ulcerative Colitis Recruiting

Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals Recruiting

Other trials for the same condition

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC Active, not recruiting

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment Active, not recruiting

CHARM Hepatocellular Carcinoma MEA Study Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06464380 on ClinicalTrials.gov ↗ ← All trials in Egypt